Sentences with phrase «ipilimumab targets»

Ipilimumab targets a protein called cytotoxic T lymphocytic antigen - 4 (CTLA - 4) that is found on a type of immune cell called a T cell.

Ipilimumab targets the CTLA - 4 checkpoint on T cells and was the first immune checkpoint inhibitor.

Not exact matches

Ipilimumab, sold as Yervoy, is an immunotherapy drug consisting of a monoclonal antibody that targets a protein receptor, CTLA - 4.

The first such drug, called ipilimumab (Yervoy), developed out of Allison's basic science research, showed much lower response rates against advanced melanoma than those obtained with targeted drugs, but long - term follow - up found that 22 percent of those treated with Yervoy survived at least four years, unprecedented results for the disease.

By targeting CTLA - 4, ipilimumab restimulates the immune system to target tumor cells.

The other major class of immunotherapies are known as anti-CTLA-4 treatments, such as ipilimumab (Yervoy), which target a different mechanism to unleash immune cells to fight tumors.

In 2011, ipilimumab (Yervoy)-- which targets the CTLA - 4 pathway — was approved by the FDA to treat unresectable or metastatic melanoma.

This discovery has inspired the development of approaches to target this pathway in patients being treated with ipilimumab.

Following the US Food and Drug Administration (FDA) approval of ipilimumab the following year, approvals of other targeted therapies (against BRAF and MEK), and most recently, approvals and extended indications for other checkpoint inhibitors, especially the programmed death 1 (PD - 1) / programmed death ligand 1 (PD - L1) inhibitors, have constituted a revolution characterized by higher response rates and the potential for extended survival.